Inceptionr LLC Acquires Shares of 5,172 Insmed, Inc. $INSM

Inceptionr LLC bought a new position in shares of Insmed, Inc. (NASDAQ:INSM) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 5,172 shares of the biopharmaceutical company’s stock, valued at approximately $846,000.

Several other institutional investors have also recently made changes to their positions in INSM. CIBC Private Wealth Group LLC lifted its position in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Insmed by 10.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 69 shares in the last quarter. ORG Partners LLC grew its position in shares of Insmed by 12.7% in the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 74 shares during the period. Private Advisor Group LLC grew its position in shares of Insmed by 1.8% in the 1st quarter. Private Advisor Group LLC now owns 4,749 shares of the biopharmaceutical company’s stock worth $777,000 after buying an additional 82 shares during the period. Finally, Allworth Financial LP increased its stake in shares of Insmed by 20.5% in the 4th quarter. Allworth Financial LP now owns 635 shares of the biopharmaceutical company’s stock worth $111,000 after acquiring an additional 108 shares in the last quarter.

Insider Transactions at Insmed

In other Insmed news, insider Michael Alexander Smith sold 1,806 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $95.82, for a total value of $173,050.92. Following the transaction, the insider directly owned 37,648 shares of the company’s stock, valued at approximately $3,607,431.36. This trade represents a 4.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 2,370 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $242,379.90. Following the completion of the transaction, the chief operating officer directly owned 98,603 shares in the company, valued at $10,084,128.81. The trade was a 2.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 54,590 shares of company stock worth $5,793,738. 2.10% of the stock is currently owned by insiders.

Insmed Trading Down 0.5%

Shares of INSM stock opened at $106.92 on Friday. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. Insmed, Inc. has a 12-month low of $90.39 and a 12-month high of $212.75. The stock has a market capitalization of $23.17 billion, a P/E ratio of -18.59 and a beta of 0.78. The firm’s 50 day moving average is $105.20 and its 200 day moving average is $133.54.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. The business had revenue of $305.96 million during the quarter, compared to analyst estimates of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company’s quarterly revenue was up 229.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.42) EPS. Research analysts expect that Insmed, Inc. will post -2.43 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on INSM shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research report on Friday, July 17th. Guggenheim restated a “buy” rating and issued a $207.00 price objective on shares of Insmed in a report on Friday, July 10th. Mizuho set a $192.00 target price on shares of Insmed in a research note on Tuesday, June 16th. Wells Fargo & Company raised their target price on shares of Insmed from $160.00 to $161.00 and gave the company an “overweight” rating in a research note on Wednesday, July 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a report on Wednesday, June 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $209.13.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.